I agree with this, but one part of the story that may be missing, which I hope an investigative journalist will write someday, is to what extent the QTC concerns were raised in bad faith by other drug companies in an attempt to de-value Geodon, which was viewed as a huge threat to the other atypical antipsychotics on the market due to its lack of metabolic side effects.
A 1/33,000 risk of death is definitely worth paying attention to. At the ~$10M statistical value of life in the US, it's like the patient paying an extra $300 out of pocket.
Great post! When I was a psychiatry resident, I tried to push back against some of the QTc stuff in this letter to the editor
Routine Corrected QT Interval Monitoring With Antipsychotic Use in Consultation-Liaison Setting: Playing the Devil’s Advocate
https://www.sciencedirect.com/science/article/pii/S0033318216301359
I agree with this, but one part of the story that may be missing, which I hope an investigative journalist will write someday, is to what extent the QTC concerns were raised in bad faith by other drug companies in an attempt to de-value Geodon, which was viewed as a huge threat to the other atypical antipsychotics on the market due to its lack of metabolic side effects.
A 1/33,000 risk of death is definitely worth paying attention to. At the ~$10M statistical value of life in the US, it's like the patient paying an extra $300 out of pocket.
Next level, this is what becoming a physician is about, getting to this level of understanding
Thank you